Psych Vivas · Consultation-liaison psychiatry
Epilepsy and psychiatry — structured clinical viva
Fellowship viva on postictal psychosis, NDDI-E depression, LEV effects, and psychopharmacology at the epilepsy interface.
On this page & tools
Target exams
Interpretation
Reveal interpretation
Leading diagnosis: postictal (peri-ictal) psychosis — seizure cluster, lucid recovery, delayed psychosis at ~48 hours. Name Logsdail–Toone timing and violence/self-harm risk.[1]
Differentials to voice: ongoing postictal delirium (less likely after clear lucid conversation), NCSE if awareness fluctuates (offer EEG), LEV-emergent behavioural toxicity contributing, interictal psychosis less likely for this tempo, forced normalisation only if seizures/EEG have dramatically normalised with inverse psychiatric worsening.[2][5]
Acute plan: safety, observation, benzodiazepines, do not stop AEDs abruptly, short-term cautious antipsychotic if needed, neurology partnership, capacity/legal principles.[6]
Depression: NDDI-E 17 is screen-positive (greater than 15); treat interictal depression with therapy ± SSRI, suicide assessment; do not leave untreated after psychosis settles.[3][7]
Drugs: discuss LEV irritability signal and possible dose/switch with neurology; avoid bupropion; clozapine only with specialist cover; SSRIs preferred for depression.[4][5]
Close the viva: joint epilepsy–psychiatry follow-up, family education on PIP recurrence, clear contingency for future clusters.[1][6]
Key points
References
- [1]Logsdail SJ, Toone BK Post-ictal psychoses. A clinical and phenomenological description Br J Psychiatry, 1988.PMID 3167343
- [2]Krishnamoorthy ES, Trimble MR, Sander JW, Kanner AM Forced normalization at the interface between epilepsy and psychiatry Epilepsy Behav, 2002.PMID 12609326
- [3]Gilliam FG, Barry JJ, Hermann BP, et al. Rapid detection of major depression in epilepsy: a multicentre study Lancet Neurol, 2006.PMID 16632310
- [4]Alper K, Schwartz KA, Kolts RL, Khan A Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports Biol Psychiatry, 2007.PMID 17223086
- [5]Mula M Epilepsy and Psychiatric Comorbidities: Drug Selection Curr Treat Options Neurol, 2017.PMID 29046989
- [6]de Toffol B, Trimble M, Hesdorffer DC, et al. Pharmacotherapy in patients with epilepsy and psychosis Epilepsy Behav, 2018.PMID 30241054
- [7]Barry JJ, Ettinger AB, Friel P, et al. Consensus statement: the evaluation and treatment of people with epilepsy and affective disorders Epilepsy Behav, 2008.PMID 18502183